Sumitomo Mitsui Trust Group’s CRISPR Therapeutics CRSP Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93.8M	Sell	1,720,734 -133,141	-7%	-$7.02M	0.05%	313
2026 Q1	$88.2M	Sell	1,853,875 -104,236	-5%	-$5.5M	0.06%	306
2025 Q4	$103M	Sell	1,958,111 -205,564	-10%	-$12.3M	0.06%	283
2025 Q3	$140M	Sell	2,163,675 -251,163	-10%	-$14.4M	0.08%	227
2025 Q2	$117M	Sell	2,414,838 -125,051	-5%	-$4.84M	0.07%	253
2025 Q1	$86.4M	Sell	2,539,889 -205,787	-7%	-$8.72M	0.06%	311
2024 Q4	$108M	Sell	2,745,676 -222,358	-7%	-$10.5M	0.07%	262
2024 Q3	$139M	Sell	2,968,034 -183,480	-6%	-$9.31M	0.1%	204
2024 Q2	$170M	Sell	3,151,514 -117,271	-4%	-$6.78M	0.13%	161
2024 Q1	$223M	Sell	3,268,785 -100,977	-3%	-$7.23M	0.15%	145
2023 Q4	$211M	Sell	3,369,762 -95,708	-3%	-$5.29M	0.16%	145
2023 Q3	$157M	Sell	3,465,470 -67,887	-2%	-$3.51M	0.13%	167
2023 Q2	$198M	Sell	3,533,357 -439,823	-11%	-$25M	0.15%	141
2023 Q1	$180M	Sell	3,973,180 -33,296	-0.8%	-$1.62M	0.13%	169
2022 Q4	$163M	Sell	4,006,476 -256,260	-6%	-$13.6M	0.13%	182
2022 Q3	$279M	Sell	4,262,736 -321,362	-7%	-$23.3M	0.23%	100
2022 Q2	$279M	Sell	4,584,098 -35,649	-0.8%	-$2.1M	0.21%	98
2022 Q1	$290M	Buy	+4,619,747	New	+$290M	0.19%	113

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group's CRSP Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its CRISPR Therapeutics (CRSP) stake by 7.2% in Q2 2026, selling an estimated $7.02M and leaving 1,720,734 shares worth $93.8M. The position accounts for 0.05% of the portfolio, ranked #313.

Sumitomo Mitsui Trust Group first reported a position in CRSP in Q1 2022 and has held it in 18 quarters since. The position peaked at $290M in Q1 2022. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Sumitomo Mitsui Trust Group held 1,720,734 shares of CRISPR Therapeutics worth $93.8M as of Q2 2026.
Sumitomo Mitsui Trust Group sold 133,141 CRISPR Therapeutics shares in Q2 2026, an estimated $7.02M.
CRISPR Therapeutics made up 0.05% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #313 holding.
Sumitomo Mitsui Trust Group first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 18 quarters since.
Sumitomo Mitsui Trust Group's CRISPR Therapeutics position peaked at $290M in Q1 2022.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.